Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%

Reuters

2025/11/14

<a href="https://laohu8.com/S/SNSE">Sensei Biotherapeutics</a> Q3 loss narrows; reduces workforce by 65%

Overview

Sensei Biotherapeutics reports Q3 net loss of $4.6 mln, down from $7.3 mln last year
Company reduces workforce by 65% to preserve cash

Outlook

Sensei Biotherapeutics exploring strategic alternatives, including asset sales and potential merger
Company implements workforce reduction to preserve cash amid strategic review
Sensei retains small team for compliance and strategic exploration

Result Drivers

WORKFORCE REDUCTION - Sensei reduced its workforce by approximately 65% to preserve cash amid strategic review
R&D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$3.62
Q3 Net Income		-$4.57 mln
Q3 Income From Operations		-$4.85 mln
Q3 Operating Expenses		$4.85 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Press Release: ID:nGNX9Xw7bX

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583051815"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583051815\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583051815?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583051815","market":"nz","top_or_hot":-1,"title":"Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> Q3 loss narrows; reduces workforce by 65%</title></head><body><p><span>Overview</span></p><ul><li><p>Sensei Biotherapeutics reports Q3 net loss of $4.6 mln, down from $7.3 mln last year</p></li><li><p>Company reduces workforce by 65% to preserve cash</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sensei Biotherapeutics exploring strategic alternatives, including asset sales and potential merger</p></li><li><p>Company implements workforce reduction to preserve cash amid strategic review</p></li><li><p>Sensei retains small team for compliance and strategic exploration</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>WORKFORCE REDUCTION - Sensei reduced its workforce by approximately 65% to preserve cash amid strategic review</p></li><li><p>R&amp;D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$3.62</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$4.57 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$4.85 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$4.85 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li></ul><p>Press Release: <span>ID:nGNX9Xw7bX</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> Q3 loss narrows; reduces workforce by 65%</title></head><body><p><span>Overview</span></p><ul><li><p>Sensei Biotherapeutics reports Q3 net loss of $4.6 mln, down from $7.3 mln last year</p></li><li><p>Company reduces workforce by 65% to preserve cash</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sensei Biotherapeutics exploring strategic alternatives, including asset sales and potential merger</p></li><li><p>Company implements workforce reduction to preserve cash amid strategic review</p></li><li><p>Sensei retains small team for compliance and strategic exploration</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>WORKFORCE REDUCTION - Sensei reduced its workforce by approximately 65% to preserve cash amid strategic review</p></li><li><p>R&amp;D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$3.62</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$4.57 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$4.85 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$4.85 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li></ul><p>Press Release: <span>ID:nGNX9Xw7bX</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ0HP:1","article_id":"2583051815","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583051815","pubTimestamp":1763123921,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%OverviewSensei Biotherapeutics reports Q3 net loss of $4.6 mln, down from $7.3 mln last yearCompany reduces workforce by 65% to preserve","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNSE":"Sensei Biotherapeutics, Inc."},"translate_title":"Sensei Biotherapeutics第三季度亏损缩小；减少65%的劳动力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNSE":0.9},"content_text":"Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%OverviewSensei Biotherapeutics reports Q3 net loss of $4.6 mln, down from $7.3 mln last yearCompany reduces workforce by 65% to preserve cashOutlookSensei Biotherapeutics exploring strategic alternatives, including asset sales and potential mergerCompany implements workforce reduction to preserve cash amid strategic reviewSensei retains small team for compliance and strategic explorationResult DriversWORKFORCE REDUCTION - Sensei reduced its workforce by approximately 65% to preserve cash amid strategic reviewR&D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$3.62Q3 Net Income-$4.57 mlnQ3 Income From Operations-$4.85 mlnQ3 Operating Expenses$4.85 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Press Release: ID:nGNX9Xw7bXFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}